Co Diagnostics Inc (CODX) 뉴스

Jan 31 short volumes: CODX 13%, FLGT 57%, QDEL 56%, VERU 45%.

Jan 30 short volumes: CODX 5%, FLGT 46%, QDEL 31%, VERU 52%.

Jan 29 short volumes: CODX 25%, FLGT 56%, QDEL 53%, VERU 59%.

Jan 28 short volumes: CODX 18%, FLGT 33%, QDEL 64%, VERU 66%.

Jan 27 short volumes: CODX 34%, FLGT 52%, QDEL 65%, VERU 68%.

Jan 24 short volumes: CODX 19%, FLGT 48%, QDEL 43%, VERU 59%.

Jan 23 short volumes: CODX 41%, FLGT 52%, QDEL 56%, VERU 42%.

Jan 22 short volumes: CODX 12%, FLGT 33%, QDEL 49%, VERU 45%.

Jan 21 short volumes: CODX 17%, FLGT 29%, QDEL 47%, VERU 45%.

Jan 17 short volumes: CODX 19%, FLGT 46%, QDEL 65%, VERU 34%.

Jan 16 short volumes: CODX 35%, FLGT 50%, QDEL 59%, VERU 31%.

Jan 15 short volumes: CODX 19%, FLGT 35%, QDEL 33%, VERU 30%.

Jan 14 short volumes: CODX 21%, FLGT 43%, QDEL 36%, VERU 42%.

Jan 13 short volumes: CODX 9%, FLGT 57%, QDEL 45%, VERU 35%.

CODX...............................https://stockcharts.com/h-sc/ui?s=CODX&p=W&b=5&g=0&id=p86431144783

Jan 10 short volumes: CODX 9%, FLGT 54%, QDEL 41%, VERU 26%.

CODX...83...Adding here...🥳...

georgie18

Member Level
Re: georgie18 post# 4136

Monday, January 06, 2025 1:20:30 PM

Post#
4137
of 4140
CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

Jan 8 short volumes: CODX 22%, FLGT 32%, QDEL 49%, VERU 47%.

Jan 7 short volumes: CODX 22%, FLGT 43%, QDEL 66%, VERU 41%.

Jan 6 short volumes: CODX 32%, FLGT 34%, QDEL 52%, VERU 42%.

CODX...$1.07...on the Breakout...🥳Off my .78 Alert...

georgie18

Member Level
Re: georgie18 post# 670539

Monday, January 06, 2025 1:15:05 PM

Post#
670570
of 670573
CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...979...HOD...🥳...Break/Hold .98 and she sere $1.10 range...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 4134

Monday, January 06, 2025 11:47:20 AM

Post#
4135
of 4135
CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...90...🥳...Trying Upper Bollie Breakout off my .78 Alert...

georgie18

Member Level
Re: None

Friday, January 03, 2025 8:17:29 PM

Post#
670368
of 670537
CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

CODX...78...🥳... https://schrts.co/nwZDVRHw ...Loading all I can under $1...Last time I bought at $1 during Covid it ran to $30...Float is in the 30 Million range...

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers® chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform*. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognize the value of the Co-Primers PCR technology and of the forthcoming testing platform."

The WHO reported that 10.8 million people fell ill from tuberculosis, or TB, in 2023, causing an estimated 1.25 million deaths. These numbers indicate that TB has likely replaced COVID-19 as the world's leading cause of death from a single infectious agent.

Co-Diagnostics' CEO Dwight Egan added "This event is an important milestone in our Company's journey to close the infectious disease diagnostics gap worldwide, and in our story coming full circle. The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesizing Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialization of our new PCR testing platform in India. We are grateful for our invaluable partners in these efforts, whose hard work has helped to bring this facility online."

Invitations to the event may be requested via info@cosara.in.

Jan 3 short volumes: CODX 47%, FLGT 34%, QDEL 61%, VERU 33%.

Jan 2 short volumes: CODX 30%, FLGT 34%, QDEL 61%, VERU 39%.

Dec 31 short volumes: CODX 35%, FLGT 33%, QDEL 56%, VERU 52%.

Dec 30 short volumes: CODX 59%, FLGT 47%, QDEL 70%, VERU 56%.

Dec 27 short volumes: CODX 28%, FLGT 37%, QDEL 48%, VERU 43%.

Dec 26 short volumes: CODX 23%, FLGT 33%, QDEL 55%, VERU 48%.

Dec 24 short volumes: CODX 40%, FLGT 10%, QDEL 54%, VERU 62%.

Dec 23 short volumes: CODX 33%, FLGT 38%, QDEL 59%, VERU 57%.

Dec 18 short volumes: CODX 38%, FLGT 36%, QDEL 40%, VERU 47%.

Dec 19 short volumes: CODX 26%, FLGT 37%, QDEL 60%, VERU 80%.

Dec 18 short volumes: CODX 42%, FLGT 52%, QDEL 66%, VERU 58%.

Dec 17 short volumes: CODX 33%, FLGT 37%, QDEL 52%, VERU 57%.

Dec 16 short volumes: CODX 19%, FLGT 26%, QDEL 29%, VERU 44%.

Dec 13 short volumes: CODX 20%, FLGT 46%, QDEL 52%, VERU 80%.

Dec 12 short volumes: CODX 21%, FLGT 41%, QDEL 51%, VERU 28%.

Dec 11 short volumes: CODX 9%, FLGT 48%, QDEL 22%, VERU 33%.

Dec 10 short volumes: CODX 23%, FLGT 51%, QDEL 46%, VERU 59%.

Dec 9 short volumes: CODX 17%, FLGT 35%, QDEL 32%, VERU 31%.

Dec 6 short volumes: CODX 16%, FLGT 29%, QDEL 57%, VERU 32%.

Dec 5 short volumes: CODX 8%, FLGT 59%, QDEL 37%, VERU 51%.

Dec 4 short volumes: CODX 15%, FLGT 43%, QDEL 45%, VERU 42%.

Dec 3 short volumes: CODX 54%, FLGT 58%, QDEL 48%, VERU 50%.

Dec 2 short volumes: CODX 10%, FLGT 62%, QDEL 37%, VERU 38%.

Nov 29 short volumes: CODX 14%, FLGT 51%, QDEL 51%, VERU 44%.

Nov 27 short volumes: CODX 34%, FLGT 60%, QDEL 26%, VERU 50%.

Nov 26 short volumes: CODX 22%, FLGT 53%, QDEL 36%, VERU 44%.